8-K: Iterum Therapeutics Reports Q1 2025 Financial Results, Prepares for Potential ORLYNVAH Launch

Iterum Therapeutics announces its Q1 2025 financial results, highlighting preparations for a potential ORLYNVAH launch in Q4 2025 and an extended cash runway into 2026.

Summary

• Iterum Therapeutics reported its financial results for the first quarter ended March 31, 2025.
• The company is preparing for a potential launch of ORLYNVAH for uncomplicated urinary tract infections (uUTIs) by the fourth quarter of 2025.
• Iterum expects its current cash resources to fund operations into 2026.
• Cash and cash equivalents were $12.7 million as of March 31, 2025.
• The company raised approximately $5 million in gross proceeds through a registered direct offering on April 30, 2025.
• An additional $1 million was raised under its at-the-market offering program from April 1, 2025, through April 22, 2025.
• Iterum repaid its 6.500% Exchangeable Senior Subordinated Notes due 2025 in January 2025.
• Cost of sales for Q1 2025 were $0.3 million, representing amortization related to the regulatory milestone payment to Pfizer.
• Research and development expenses for Q1 2025 were $0.6 million, compared to $4.0 million in Q1 2024.
• General and administrative expenses for Q1 2025 were $2.8 million, compared to $2.2 million in Q1 2024.
• The net loss for Q1 2025 was $4.9 million, compared to a net loss of $7.1 million for the same period in 2024.
• The non-GAAP net loss for Q1 2025 was $3.3 million, compared to a non-GAAP net loss of $5.8 million for the same period in 2024.
• As of May 12, 2025, Iterum had approximately 40.0 million ordinary shares outstanding.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive. The company is preparing for a product launch and has extended its cash runway, but it is still operating at a loss and requires additional funding.

Positives

• Iterum is preparing for the potential launch of ORLYNVAH in Q4 2025, which could provide a new treatment option for uUTIs.
• The company's cash runway extends into 2026, providing financial stability.
• Iterum successfully repaid its Exchangeable Notes in January 2025, reducing its debt burden.
• The company raised additional capital through a registered direct offering and an at-the-market offering program.
• Research and development expenses decreased significantly compared to the same period in the previous year.

Negatives

• The company reported a net loss of $4.9 million for Q1 2025, although this is an improvement compared to the $7.1 million loss in Q1 2024.
• General and administrative expenses increased due to pre-commercialization activities, impacting profitability.

Risks

• The success of the potential ORLYNVAH launch depends on securing a commercial partner or building a sales force.
• The company's ability to continue as a going concern is dependent on its ability to raise sufficient capital and successfully commercialize ORLYNVAH.
• The market acceptance of ORLYNVAH is uncertain.
• Iterum faces risks related to regulatory requirements and decisions, as well as the actions of third-party organizations.

Future Outlook

Iterum expects its cash resources to fund operations into 2026 and is preparing for a potential launch of ORLYNVAH by Q4 2025.

Management Comments

• Based on pre-commercialization work completed to date, we expect to be able to launch ORLYNVAHTM for the treatment of uncomplicated urinary tract infections (uUTIs) by the fourth quarter of this year, said Corey Fishman, Iterums Chief Executive Officer.
• While we continue to pursue our strategy of seeking a strategic transaction acceptable to our Board, there is an urgency to bring ORLYNVAHTM to the U.S. market to serve patients suffering with uUTIs who have limited or no treatment options given the lack of innovation over the past 25 years and the increasing rate of antimicrobial resistance to the generic drugs used to treat uUTIs today.

Industry Context

Iterum is focused on addressing the growing problem of multi-drug resistant pathogens, a significant concern in both community and hospital settings. The potential launch of ORLYNVAH aims to provide a new treatment option for uUTIs, where resistance to existing antibiotics is increasing.

Comparison to Industry Standards

• It is difficult to compare Iterum's results directly to industry standards without knowing the specific stage and focus of comparable companies.
• However, companies like Nabriva Therapeutics and Achaogen (prior to its bankruptcy) also focused on developing novel antibiotics to combat drug-resistant infections.
• The success of ORLYNVAH will depend on its ability to gain market share against existing treatments and demonstrate a clear clinical benefit in addressing antibiotic resistance, similar to how Paratek Pharmaceuticals' Nuzyra has been positioned.

Stakeholder Impact

• Shareholders may be impacted by the potential commercial success of ORLYNVAH and the company's ability to secure funding.
• Patients with uUTIs could benefit from a new treatment option if ORLYNVAH is successfully launched.
• Employees are affected by the company's strategic decisions and its ability to continue operations.

Next Steps

• Iterum will continue pre-commercialization activities for ORLYNVAH.
• The company will prepare for a potential commercial launch of ORLYNVAH in Q4 2025.
• Iterum will continue to evaluate strategic alternatives for its sulopenem assets.
• Iterum will host a conference call to discuss the financial results.

Key Dates

Keywords

Iterum Therapeutics, ORLYNVAH, sulopenem, uUTIs, financial results, cash runway, antibiotics, FDA approval, registered direct offering, at-the-market offering